Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does ERLOTINIB Cause International normalised ratio increased? 12 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 12 reports of International normalised ratio increased have been filed in association with ERLOTINIB (Erlotinib). This represents 0.1% of all adverse event reports for ERLOTINIB.

12
Reports of International normalised ratio increased with ERLOTINIB
0.1%
of all ERLOTINIB reports
3
Deaths
3
Hospitalizations

How Dangerous Is International normalised ratio increased From ERLOTINIB?

Of the 12 reports, 3 (25.0%) resulted in death, 3 (25.0%) required hospitalization.

Is International normalised ratio increased Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for ERLOTINIB. However, 12 reports have been filed with the FAERS database.

What Other Side Effects Does ERLOTINIB Cause?

Death (5,000) Rash (4,648) Diarrhoea (3,448) Fatigue (1,548) Nausea (1,366) Drug ineffective (1,207) Off label use (1,190) Decreased appetite (998) Malignant neoplasm progression (954) Dry skin (953)

What Other Drugs Cause International normalised ratio increased?

WARFARIN (5,622) RIVAROXABAN (863) ACETAMINOPHEN (533) ASPIRIN (448) APIXABAN (317) CLOPIDOGREL BISULFATE (314) FLUINDIONE (286) AMIODARONE (277) FUROSEMIDE (277) DABIGATRAN ETEXILATE (223)

Which ERLOTINIB Alternatives Have Lower International normalised ratio increased Risk?

ERLOTINIB vs ERTAPENEM ERLOTINIB vs ERTUGLIFLOZIN PIDOLATE ERLOTINIB vs ERYTHROMYCIN ERLOTINIB vs ERYTHROMYCIN ETHYLSUCCINATE ERLOTINIB vs ERYTHROMYCIN LACTOBIONATE

Related Pages

ERLOTINIB Full Profile All International normalised ratio increased Reports All Drugs Causing International normalised ratio increased ERLOTINIB Demographics